Biogen Ups Samsung Bioepis Stake In $700m Bet On Biosimilars
While Biogen's exercise of its call option in biosimilar joint venture Samsung Bioepis may help further boost the biosimilar company's global presence and leadership in the sector, the focus in South Korea is more on how the change may affect the outcome of an ongoing accounting inspection at Samsung BioLogics, Samsung Bioepis' biggest shareholder.
You may also be interested in...
South Korean financial authorities conclude Samsung BioLogics violated accounting standards by omitting certain information on its joint venture agreement with Biogen from public disclosures, and have ordered further investigation of a corporate governance decision on the handling in accounts of the JV, Samsung Bioepis. The latest ruling in the prolonged affair could hurt the credibility and business of Samsung BioLogics going forward, although the firm maintains it has done nothing improper.
China’s Everest licenses global rights to Novartis FGFR4 inhibitor, while Altogen and Lynkogen partner in NASH and metabolic disease.
Celgene makes play into RNA-expression correction via neuroscience partnership and equity investment with Skyhawk. Novartis’ Sandoz agreed to commercialize Adamis’ Symjepi, a competitor to EpiPen, in the US.